Last reviewed · How we verify
FOLFOXIRI + Bevacizumab
FOLFOXIRI is a combination chemotherapy regimen that inhibits DNA synthesis and cell division, while bevacizumab blocks angiogenesis by inhibiting vascular endothelial growth factor (VEGF).
FOLFOXIRI is a combination chemotherapy regimen that inhibits DNA synthesis and cell division, while bevacizumab blocks angiogenesis by inhibiting vascular endothelial growth factor (VEGF). Used for Metastatic colorectal cancer.
At a glance
| Generic name | FOLFOXIRI + Bevacizumab |
|---|---|
| Also known as | Bevacizumab, Irinotecan, Oxaliplatin, 5-Fluorouracil |
| Sponsor | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) |
| Drug class | Chemotherapy combination + monoclonal antibody (anti-VEGF) |
| Target | DNA (chemotherapy); VEGF (bevacizumab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FOLFOXIRI combines three chemotherapy agents (5-fluorouracil, oxaliplatin, and irinotecan) that work through different mechanisms to damage cancer cell DNA and prevent replication. Bevacizumab is a monoclonal antibody that binds to VEGF, preventing tumor blood vessel formation and starving tumors of nutrients. Together, they provide dual anti-cancer activity through cytotoxic chemotherapy and anti-angiogenic mechanisms.
Approved indications
- Metastatic colorectal cancer
Common side effects
- Neutropenia
- Diarrhea
- Nausea/vomiting
- Peripheral neuropathy
- Hypertension
- Proteinuria
- Fatigue
Key clinical trials
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer (PHASE3)
- Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status (PHASE4)
- A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation (PHASE2)
- FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. (PHASE3)
- Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC (PHASE2)
- FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients (PHASE2)
- Conversion From Unresectable To Resectable Metastatic Colorectal Cancer. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: